Skip to main content

Dianthus Therapeutics, Inc.

DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001690585

In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Dianthus Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of DNTH: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders99103+4
Shares37.7M39.1M+1.39M (+3.7%)
Value$685.5M$728.6M+$43.1M (+6.3%)

New holders (18)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to DNTH in Q2 2025
InstitutionSharesValue% of portfolio
Baker Bros. Advisors LP789,759$14.7M0.14%
Millennium Management LLC195,357$3.64M0.00%
Schonfeld Strategic Advisors LLC172,039$3.21M0.02%
Ensign Peak Advisors, Inc134,416$2.50M0.00%
ExodusPoint Capital Management, LP75,079$1.40M0.02%
Ameriprise Financial Inc56,261$1.05M0.00%
Paloma Partners Management Co29,214$544.3K0.12%
XTX Topco Ltd27,003$503.1K0.02%
Verition Fund Management LLC22,945$427.5K0.00%
Quest Partners LLC5,028$93.7K0.01%
Aquatic Capital Management LLC3,187$59.4K0.00%
Raymond James Financial Inc1,430$26.6K0.00%
Point72 Asia (Singapore) Pte. Ltd.1,014$18.9K0.00%
Caitong International Asset Management Co., Ltd356$6.63K0.00%
Quarry LP137$2.55K0.00%
Riggs Asset Managment Co. Inc.35$6530.00%
Principal Securities, Inc.11$2050.00%
Signaturefd, LLC8$1490.00%

Sold out (14)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.